Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 499 of 5804
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
Phase: PHASE1, PHASE2 • Sponsor: Salubris Biotherapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug mosunetuzumab takes on standard therapy in lymphoma trial
Disease control Recruiting nowThis phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and s…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail shows promise for recurrent ovarian and endometrial cancers
Disease control Recruiting nowThis is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in comb…
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control Recruiting nowAdult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or blastic plasmocytoid dentritic cell neoplasm will be recruited in the trial. CART123 cells will be manufatured …
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for pancreatic cancer: EXPAND trial targets limited metastases
Disease control Recruiting nowThe EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for kidney patients: targeted drug may replace harsh chemotherapy
Disease control Recruiting nowThis is a randomized, parallel group, active-controlled, open-label, Phase III study comparing the efficacy and safety of obinutuzumab versus cyclophosphamide combined with glucocorticoids in patients with primary membranous nephropathy (pMN). Approximately 144 patients with pMN …
Phase: PHASE3 • Sponsor: Huashan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Blood test could replace risky needle for prenatal genetic diagnosis
Diagnosis Recruiting nowCell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnos…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Weight loss may shield down syndrome adults from Alzheimer's
Prevention Recruiting nowThe goal of this study is to determine if weight loss or changes in dietary intake can help prevent of delay adults with Down syndrome from developing Alzheimer's Disease Adults with Down syndrome without dementia will be randomized to either a weight loss group or a general hea…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
New hope for advanced prostate cancer: drug combo trial launches
Disease control Recruiting nowDespite improvements in treatment, metastatic prostate cancer remains incurable, especially in the case of pretreated metastatic castration-resistant disease (mCRPC), where treatment options are limited, leading to an unmet need. The paradigm shift in the treatment of metastatic …
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control Recruiting nowThis will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) i…
Phase: PHASE1, PHASE2 • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo shows promise for rare, aggressive blood cancer
Disease control Recruiting nowExtranodal NK/T-cell lymphoma is a rare and highly aggressive subtype of non-Hodgkin lymphoma. While the overall survival rates have improved for early-stage ENKTL patients, the prognosis for those with advanced disease remains poor, and there is currently no standard treatment. …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Radioactive therapy targets stubborn leukemia in early trial
Disease control Recruiting nowCXCR4 inhibition may represent a new therapeutic strategy in acute leukemia (AL) patients, not only by increasing chemosensitivity but also by preventing relapse of the disease by disruption of the interaction of residual leukemic cells with the bone marrow niche. Radiolabeled CX…
Phase: PHASE1, PHASE2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New eye drug aims to cut injection frequency for wet AMD patients
Disease control OngoingThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for babies with severe epilepsy: fenfluramine safety trial launches
Disease control Recruiting nowDravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in the first year of life with prolonged seizures, often hemiclonic and in the sett…
Phase: PHASE4 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control OngoingThe main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could less radiation be enough? new trial hopes to reduce side effects for kids with brain tumors
Disease control Recruiting nowThis phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and …
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New daily pill could ease sleep apnea for those with excess weight
Disease control OngoingStudy GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have modera…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo aims to stall prostate cancer spread
Disease control Recruiting nowThis study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can cannabis compounds help tame opioid cravings and chronic pain?
Symptom relief Recruiting nowThe primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid craving in people with co-occurring opioid use disorder (…
Phase: PHASE2 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New antibody combo tackles tough leukemia
Disease control Recruiting nowThe planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2). Basically, the study aims to develop data for optimization of first-line therapy of T-ALL, eithe…
Phase: PHASE2 • Sponsor: Goethe University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC